Hailiang Hu

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Venues

Cell death & disease

Clinical and translational medicine

Cancers

Proceedings of the National Academy of Sciences of the United States of America

Duke University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Duke University

United States

Assistant Professor :: Pathology

Publications

Haozhe Zhang, Yi Zhou, Yating Feng, Wenli Hou, Yafei Chen, Zengzhen Xing, Yifan Zhang, Qiang Wei, Yu Yin, Ju Guo, Hailiang Hu
Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Clinical and translational medicine 14 (5) (2024)
Haozhe Zhang, Yi Zhou, Yating Feng, Wenli Hou, Yafei Chen, Zengzhen Xing, Yifan Zhang, Qiang Wei, Yu Yin, Ju Guo, Hailiang Hu
Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Clinical and translational medicine 14 (5) (2024)
Haozhe Zhang, Yi Zhou, Yating Feng, Wenli Hou, Yafei Chen, Zengzhen Xing, Yifan Zhang, Qiang Wei, Yu Yin, Ju Guo, Hailiang Hu
Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Clinical and translational medicine 14 (5) (2024)
Haozhe Zhang, Yi Zhou, Yating Feng, Wenli Hou, Yafei Chen, Zengzhen Xing, Yifan Zhang, Qiang Wei, Yu Yin, Ju Guo, Hailiang Hu
Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Clinical and translational medicine 14 (5) (2024)
Shuai Yuan, Shu Xi, Hong Weng, Meng-Meng Guo, Jin-Hui Zhang, Zhi-Ping Yu, Haozhe Zhang, Zhaojun Yu, Zengzhen Xing, Meng-Yang Liu, Dao-Jing Ming, Rajiv Kumar Sah, Yi Zhou, Yi-Gang Li, Tao Zeng, Xin Hong, Yafei Li, Xian-Tao Zeng, Hailiang Hu
YTHDC1 as a tumor progression suppressor through modulating FSP1-dependent ferroptosis suppression in lung cancer. Cell death and differentiation (2023)
Shuai Yuan, Shao-Hua He, Lu-Yao Li, Shu Xi, Hong Weng, Jin-Hui Zhang, Dan-Qi Wang, Meng-Meng Guo, Haozhe Zhang, Shuang-Ying Wang, Dao-Jing Ming, Meng-Yang Liu, Hailiang Hu, Xian-Tao Zeng
A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m 6 A reader YTHDC1. Cell death & disease 14 (1) (2023)
Shuai Yuan, Shao-Hua He, Lu-Yao Li, Shu Xi, Hong Weng, Jin-Hui Zhang, Dan-Qi Wang, Meng-Meng Guo, Haozhe Zhang, Shuang-Ying Wang, Dao-Jing Ming, Meng-Yang Liu, Hailiang Hu, Xian-Tao Zeng
A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m 6 A reader YTHDC1. Cell death & disease 14 (1) (2023)
Shuai Yuan, Shao-Hua He, Lu-Yao Li, Shu Xi, Hong Weng, Jin-Hui Zhang, Dan-Qi Wang, Meng-Meng Guo, Haozhe Zhang, Shuang-Ying Wang, Dao-Jing Ming, Meng-Yang Liu, Hailiang Hu, Xian-Tao Zeng
A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m 6 A reader YTHDC1. Cell death & disease 14 (1) (2023)
Shuai Yuan, Shao-Hua He, Lu-Yao Li, Shu Xi, Hong Weng, Jin-Hui Zhang, Dan-Qi Wang, Meng-Meng Guo, Haozhe Zhang, Shuang-Ying Wang, Dao-Jing Ming, Meng-Yang Liu, Hailiang Hu, Xian-Tao Zeng
A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m 6 A reader YTHDC1. Cell death & disease 14 (1) (2023)
Shuai Yuan, Shao-Hua He, Lu-Yao Li, Shu Xi, Hong Weng, Jin-Hui Zhang, Dan-Qi Wang, Meng-Meng Guo, Haozhe Zhang, Shuang-Ying Wang, Dao-Jing Ming, Meng-Yang Liu, Hailiang Hu, Xian-Tao Zeng
A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m 6 A reader YTHDC1. Cell death & disease 14 (1) (2023)
Haozhe Zhang, Yi Zhou, Zengzhen Xing, Rajiv Kumar Sah, Junqi Hu, Hailiang Hu
Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance. International journal of molecular sciences 23 (21) (2022)
Lingfan Xu, Yu Yin, Yanjing Li, Xu-Feng Chen, Yan Chang, Hong Zhang, Juan Liu, James Beasley, Patricia McCaw, Haoyue Zhang, Sarah P Young, Jeff Groth, Qianben Wang, Jason W Locasale, Xia Gao, Dean G Tang, Xuesen Dong, Yiping He, Daniel George, Hailiang Hu, Jiaoti Huang
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 118 (13) (2021)
Huan Xu, Sangsang Li, Yi Sun, Lingfan Xu, Xin Hong, Zhong Wang, Hailiang Hu
ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer. Cancers 13 (16) (2021)
Jun A, Zhiqian Zhang, Zhiqian Zhang, Hailiang Hu, Jin-Tang Dong
Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer. Cancers 13 (4) (2021)
Yanjing Li, Yiping He, William Butler, Lingfan Xu, Yan Chang, Kefeng Lei, Hong Zhang, Yinglu Zhou, Allen C Gao, Qingfu Zhang, Daniel G Taylor, Donghui Cheng, Suzette Farber-Katz, Rachid Karam, Tyler Landrith, Bing Li, Sitao Wu, Vickie Hsuan, Qing Yang, Hailiang Hu, Xu-Feng Chen, Melissa Flowers, Shannon J McCall, John K Lee, Bryan A Smith, Jung Wook Park, Andrew S Goldstein, Qianben Wang, Matthew B Rettig, Andrew J Armstrong, Qing Cheng, Jiaoti Huang
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Science translational medicine 11 (521) (2020)

Hailiang Hu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hailiang Hu